Engflag

Florgan

Quick links to important sections

Florgan

Florgan_EN

Method of action: Antiallergic, Antiexudative, Antihistamines For Systemic Use, Antipruritic, H1-Antihistamine

Treatment option: Allergic Reactions, Allergic Conjunctivitis, Hives, Fever, Rhinitis, Hay Fever

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Florgan

Florgan is a single-ingredient medicinal entity formulated for systemic relief of allergic discomfort, with the exclusive active ingredient being the compound Loratadine. This medication is clinically recognized as a second-generation antihistamine, functioning as a selective peripheral Histamine H1-receptor antagonist. Florgan is typically available for oral administration in multiple forms, including tablets and as an oral solution or syrup.

What Type of Medicine is Florgan (Loratadine)?

Florgan belongs to the class of second-generation antihistamines, a group developed for enhanced receptor specificity and reduced central nervous system (CNS) impact. The active substance, Loratadine, is a synthetic, long-acting tricyclic piperidine derivative. This structure is a differentiating factor, as it means the drug minimally crosses the blood-brain barrier. Pharmacological profiles indicate its designation as a non-sedating H1-antagonist, ensuring that the medication can provide necessary allergic relief while limiting the central nervous system effects often associated with older antihistamines.

Composition, Origin, and Available Forms

The therapeutic action of Florgan is derived entirely from its single active ingredient, Loratadine, confirming it as a monotherapy product. Loratadine has an established safety and efficacy profile across various pharmaceutical formulations. The medication is supplied in multiple oral dosage forms: solid tablets and an oral solution or syrup suspended in an aqueous vehicle, which is particularly important for patients who have difficulty swallowing tablets.

General Purpose and Mechanism Summary

The general purpose of Florgan is to provide effective, sustained relief by mitigating allergic responses throughout the body. It achieves this by acting as a competitive inhibitor, binding to the Histamine H1-receptors that are activated by the release of histamine during an allergic reaction. By selectively blocking the histamine signal at the peripheral receptors, Florgan prevents the initiation of the physiological effects responsible for allergic discomfort, thereby offering continuous therapeutic benefit.

Regulatory References

  1. [(PubChem, NIH)]
  2. European Medicines Agency (EMA)
  3. [(EMA Public Assessment Report)]

What side effects are possible with Florgan?

Possible side effects and safety information

The official safety profile for Florgan (Loratadine) is established through regulatory classifications that document adverse reactions by frequency and physiological system.

Frequency-Classified Adverse Reactions

The most frequently reported side effects in adults and adolescents, classified as Common in regulatory documents, include headache, somnolence (drowsiness), and fatigue. Other common effects include increased appetite and insomnia.

Reactions categorized as Very Rare (affecting up to 1 in 10,000 people) include events such as dizziness, convulsion, tachycardia (rapid heartbeat), palpitation, nausea, dry mouth, gastritis, and abnormal hepatic function. Adverse reactions associated with the skin and subcutaneous tissue, such as rash and alopecia (hair loss), are also classified as very rare.

Serious Adverse Reactions

The most clinically significant adverse reactions documented in regulatory post-marketing surveillance are severe Hypersensitivity reactions, including Anaphylaxis and Angioedema (swelling of the face, lips, or throat). These events are classified as very rare.

Population-Specific Safety Considerations

Specific caution is advised in the official label for patients with severe hepatic impairment or renal disease, as an initial dose adjustment or reduced dosing frequency may be necessary. For women who are breast-feeding, the use of Loratadine is generally not recommended, as the active substance is excreted in breast milk. The safety and efficacy of the medication have not been established for children under two years of age. Additionally, certain chewable formulations may contain phenylalanine and require caution in individuals with phenylketonuria (PKU).

Safety-Related Restriction

To prevent interference with test results, Loratadine must be discontinued for a defined period (typically 48 hours or more, depending on the specific test protocol) prior to undergoing allergy skin testing.

Overdose and Emergency Response

Overdose Scope

Documented Content Official Regulatory Statement
Overdose Presentations The most reported clinical signs include somnolence (drowsiness), headache, and tachycardia (rapid heart rate). Overdosage increases the occurrence of anticholinergic symptoms, such as mydriasis and agitation.
Physiological Systems Affected Overdose impacts the Central Nervous System (CNS) and Cardiovascular System. Serious outcomes include the potential for cardiotoxicity (QT-interval prolongation) and rare reports of convulsions.
Population-Specific Notes The potential for cardiotoxicity is elevated in the elderly. Patients with severe hepatic or renal impairment may be more susceptible to toxicity due to reduced drug clearance.
Emergency-Response No specific antidote is known. Treatment consists of immediate symptomatic and supportive measures, which may involve the administration of activated charcoal or procedures like gastric lavage.
Urgent Medical Help Required Patients must seek medical help or contact a Poison Control Center right away in the event of suspected or known overdose.

Overdose Classifications (High-Level)

Classification Regulatory Context
Severity Classification The profile includes manifestations ranging from common overdose symptoms to serious, life-threatening cardiovascular and neurological complications.
Overdose-Context Constraints Medical monitoring of the patient must be continued after emergency treatment, with cardiac monitoring required for patients with suspected cardiotoxicity.

Resulting Overdose Structure

Official overdose statements:

  • Overdose is principally characterized by the documented clinical signs of somnolence, headache, and tachycardia.
  • The label requires that symptomatic and supportive measures be instituted promptly, as no specific antidote is known.
  • Patients must seek medical help immediately, triggering the necessary actions outlined in the official overdose management guidance.
  • Management procedures that may be considered include activated charcoal administration and gastric lavage.

Connection to the overall overdose profile: Regulatory documents define the Loratadine overdose profile based strictly on documented clinical effects and potential severe systemic complications. The guidance requires the immediate seeking of medical help for suspected overdose, initiating an immediate treatment protocol focused on symptomatic and supportive care and continued medical observation, as mandated by the prescribing information.

Therapeutic Uses of Florgan

Quick Facts

  • Primary Focus: Restoration of intestinal microflora balance.
  • Condition Management: May be used to help manage diarrhea associated with antibiotic use.
  • Supporting Role: Supports maintenance of a healthy balance of bacteria in the gastrointestinal tract.

What Florgan Treats: Main Uses and Benefits

Florgan is an agent used to support the normal balance of microorganisms, or flora, within the gastrointestinal system. This product may be used in contexts where this natural balance has been disrupted, such as during antibiotic administration. The primary therapeutic domain of Florgan is the management of bowel problems, specifically to help relieve episodes of diarrhea.

Similar formulations are often utilized to provide relief from various forms of diarrhea, including that linked to the use of antibiotics or travel-related circumstances. The intended benefit is to maintain a healthy internal environment by encouraging the presence of beneficial bacteria.

Patients should be aware that the use of such agents is one available option among various therapeutic approaches for gastrointestinal support. A qualified healthcare professional can provide further guidance on its use.

Regulatory References

  1. NIH MedlinePlus guidance on lactobacillus

Eligibility and Restrictions for Use

Who can and cannot use Florgan?

Florgan (Loratadine) eligibility is strictly defined by regulatory authorities based on age, physiological status, and underlying conditions.

Contraindications and Age Limits

Use of Florgan is contraindicated for patients with a documented hypersensitivity to the active ingredient, Loratadine, or any of the product's excipients. Safety and efficacy have not been established for children under 2 years of age. For other age groups, the medicine is approved for adults, adolescents, and children two years and older, with specific oral formulations approved for those 2 to 5 years old.

Use Restrictions and Special Populations

Use is restricted in patients with severe liver impairment or severe renal impairment, as these conditions typically require a regulatory-recommended lower initial dose due to altered drug clearance. Formulations containing specific excipients, such as aspartame, must be avoided by patients with Phenylketonuria (PKU). The medicine is not recommended for women who are breast-feeding because the active substance is excreted in breast milk, and use during pregnancy should be avoided as a precaution.

What should I know about interactions with other medicines?

The official regulatory profile for Florgan (Loratadine) details specific pharmacokinetic and procedural constraints for co-administration with other substances. Loratadine is metabolized predominantly by the hepatic enzyme CYP3A4 and, to a lesser extent, by CYP2D6. Co-administration with medicines that inhibit these metabolic pathways, including Ketoconazole, Erythromycin, and Cimetidine, results in substantially increased plasma concentrations of Loratadine and its active metabolite. This metabolic inhibition is officially classified as a clinically significant pharmacokinetic interaction.

Regulatory documents also cite a significant pharmacokinetic food effect: ingestion of a high-fat meal can increase the overall drug exposure (AUC) of Loratadine by approximately 40% to 76%. For procedural integrity, a timing separation rule applies: administration must be discontinued at least 48 hours prior to allergy skin tests to prevent the antihistamine effect from interfering with diagnostic results.

Regarding other substances, official studies show Loratadine has no potentiating effects on psychomotor performance when administered concurrently with alcohol. Special considerations are noted for patients with severe hepatic failure or severe renal impairment (GFR less than 30 mL/min), as impaired clearance in these populations may heighten the risk of drug accumulation.

Mechanism of Action

Mechanism of Action: How Florgan Works

Florgan operates primarily within the gastrointestinal lumen and at the intestinal mucosal surface, delivering specific microbial strains that initiate competitive exclusion against opportunistic microorganisms. These active strains metabolize complex substrates to produce Short-Chain Fatty Acids (SCFAs), notably butyrate. SCFAs serve as the main energy source for colonocytes, enhancing the integrity of tight junctions and resulting in reduced epithelial permeability.

Simultaneously, the new flora interacts with the Gut-Associated Lymphoid Tissue (GALT). This engagement modulates local immune cell activity, promoting regulatory immune signaling and contributing to the down-regulation of specific inflammatory mediators within the mucosal tissue. This cascade restores balance to key physiological parameters of the GI system, influencing the signaling dynamics along the Gut-Host Symbiosis Axis

Dosage and Administration Information

How Florgan (Loratadine) is Used: Administration Guidelines

Florgan is used according to specific instructions that govern its route, frequency, and dose.

Administration Scope

Instruction Domain Guideline
Route of administration For oral use exclusively.
Dosing schedule Adults 6 years and older: 10 mg once daily. Children 2 to 5 years: 5 mg once daily.
Timing in relation to meals May be taken without regard to mealtime (with or without food).
Preparation requirements Oral Solution/Syrup: Requires precise volumetric measurement. Orally Disintegrating Tablets (ODT): Dissolve on the tongue, and can be swallowed with or without water.

Special Procedural Conditions

Administration of Florgan is subject to specific constraints regarding patient health status and medical procedures:

  • Hepatic or Renal Impairment: For patients diagnosed with severe hepatic impairment or significant renal impairment (GFR <30 mL/min), a dose reduction is required. The initial prescribed dose is typically adjusted to 10 mg every other day for eligible patients.
  • Allergy Testing: The drug must be discontinued at least 48 hours prior to scheduled skin-prick allergy testing, as the presence of the antihistamine may interfere with the test results.
  • Missed Dose: If a dose is missed, it should be taken when remembered, but the user must ensure that no more than the maximum daily dose is taken within a 24-hour period.

Procedural Summary

The standard procedure involves once-daily oral administration of the specified 5 mg or 10 mg dose. This administration is designed to deliver a therapeutic effect that lasts in excess of 24 hours. The established instructions define the required dose modifications for certain populations and procedural constraints necessary to maintain the integrity of medical testing.

Recent Clinical Evidence

Research evidence / Overview of studies for Florgan

Evidence for Use in Allergic Rhinitis (Hay Fever)

The research base for Florgan (Loratadine) in allergic rhinitis is drawn from a large number of Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. These studies monitored specific patient-reported outcomes describing perceived discomfort, focusing on the changes measured during the study period, particularly for nasal symptoms like sneezing, runny nose (rhinorrhea), and nasal itching.

Findings describe patterns observed in the studies where data show patterns related to measured scores that evolved differently in the Florgan groups compared to placebo groups over short-term periods (typically two to four weeks). Research explores short-term symptom changes for these key allergic symptoms. However, research exploring the outcomes related to nasal congestion (stuffiness) is limited, and findings were mixed when this particular symptom was measured.

Evidence for Use in Chronic Urticaria (Hives)

Florgan was evaluated in studies for its use in Chronic Urticaria (hives), a condition marked by functional limitations. The studies monitored outcomes related to physical discomfort, specifically evaluating patient-reported outcomes describing the perceived discomfort from pruritus (itching) and the visibility and extent of wheals (hives) on the skin.

Clinical trials reported measurements where studies report how symptoms evolved in the observed populations. This evidence contributes to the broader evidence landscape describing how these conditions are studied. The main limitations here include that follow-up durations were limited, often extending only a few weeks to three months, and there is limited information for long-term changes.

Research Gaps and Areas of Uncertainty

Evidence highlights what is known—and what is still uncertain. One key research limitation frame is that the results apply only to the populations studied, meaning findings do not determine whether an individual outside of the studied criteria will respond similarly. Long-term effects are not fully established, especially regarding the long-term changes in chronic urticaria. Furthermore, comparative evidence is lacking in the clinical literature to definitively characterize Florgan's effect on certain outcomes compared to the newest therapeutic options.

How should Florgan be stored and disposed of?

How to Store and Dispose of Florgan

Official labeling requires Florgan (Loratadine) to be stored at a controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), with excursions permitted up to 30 C (86 F). The product must be kept from freezing and protected from excessive moisture and light, which requires storage in its original container, tightly closed.

Storage Restriction Requirement
Temperature Controlled Room Temperature (20 C to 25 C)
Environmental Protect from moisture, light, and do not freeze
Container Keep in original container, tightly closed

Regulatory documents mandate that the medication be stored out of the sight and reach of children using safety caps and secure locations. For disposal of unused or expired Florgan, the preferred method is a drug take-back program. If this is unavailable, the medicine is to be mixed with an undesirable substance (e.g., kitty litter) and sealed in a container for disposal in the household trash, as Florgan is not on the FDA flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagSlovenia

Equivalent of Florgan found in:

A-Z Index: